Augmenix said it won CE Mark approval in Europe for its TraceIT fiducial marker and TraceIT gel system radiology marking agents.
Massachusetts-based Augmenix is hoping it can make it to the U.S. market with the $10.8 million funding round it just closed, the company said this month.
Here’s a roundup of the latest dealflow and investment news:
Augmenix Inc. announced the first commercial implantation of its SpaceOAR prostate-rectum separation hydrogel system in Europe.
Doctors at Germany’s Aachen University Hospital implanted the CE Mark-approved absorbable spacer system, designed to protect tissue underneath the prostate during radiation therapy, according to the company.